Guggenheim Initiates Coverage on Repligen (NASDAQ:RGEN)

Guggenheim initiated coverage on shares of Repligen (NASDAQ:RGEN) in a research note released on Tuesday, Marketbeat Ratings reports. The firm issued a neutral rating on the biotechnology company’s stock.

Other analysts have also issued research reports about the stock. JPMorgan Chase & Co. dropped their target price on shares of Repligen from $230.00 to $200.00 and set an overweight rating on the stock in a research report on Thursday, May 2nd. Stifel Nicolaus lifted their target price on shares of Repligen from $165.00 to $207.00 and gave the company a buy rating in a research report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $197.75.

Repligen Stock Down 1.1 %

RGEN stock opened at $123.00 on Tuesday. The firm has a market cap of $6.87 billion, a PE ratio of 492.02, a P/E/G ratio of 4.19 and a beta of 1.04. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. The firm’s fifty day moving average is $158.40 and its 200 day moving average is $176.02. Repligen has a one year low of $110.45 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. During the same quarter last year, the business earned $0.64 EPS. The firm’s revenue for the quarter was down 17.1% compared to the same quarter last year. On average, research analysts forecast that Repligen will post 1.46 EPS for the current year.

Insider Transactions at Repligen

In other Repligen news, Director Martin D. Madaus purchased 1,615 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were purchased at an average cost of $124.94 per share, with a total value of $201,778.10. Following the completion of the purchase, the director now owns 4,613 shares in the company, valued at approximately $576,348.22. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Anthony Hunt bought 2,000 shares of Repligen stock in a transaction on Friday, June 14th. The shares were bought at an average cost of $124.08 per share, with a total value of $248,160.00. Following the completion of the purchase, the chief executive officer now directly owns 165,177 shares of the company’s stock, valued at $20,495,162.16. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Martin D. Madaus bought 1,615 shares of Repligen stock in a transaction on Friday, June 14th. The shares were purchased at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the purchase, the director now directly owns 4,613 shares of the company’s stock, valued at $576,348.22. The disclosure for this purchase can be found here. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently bought and sold shares of the company. YHB Investment Advisors Inc. purchased a new stake in shares of Repligen in the 1st quarter valued at approximately $26,000. Lazard Asset Management LLC raised its stake in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 136 shares during the period. Benjamin F. Edwards & Company Inc. raised its stake in shares of Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 146 shares during the period. Principal Securities Inc. purchased a new stake in shares of Repligen in the 4th quarter valued at approximately $48,000. Finally, CWM LLC raised its stake in shares of Repligen by 19.9% in the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 60 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.